I-Derm Pharma
First-in-Class Oral Therapy for Inflammatory Autoimmune Skin Diseases
StartupI-Derm Pharma is a Nazareth-based startup in the Health Tech & Life Sciences sector, established in 2022. First-in-Class Oral Therapy for Inflammatory Autoimmune Skin Diseases. I-Derm Pharma was founded by Ofer Sarig and Eli Sprecher. Key investors include NGT HealthCare II. The company has 1-10 employees. Core technologies: Biologicals, Molecules.
The company follows a B2B2C business model. Product stage: R&D. The company holds 1 patent.
- StagePre-Seed
- ProductR&D
- ModelB2B2C
- Employees1-10
- HQNazareth
- Last RoundUndisclosed
- NGT HealthCare IILead
Ofer SarigCo-founder & Scientific Advisor
Eli SprecherCo-founder & Scientific and Clinical Advisor
What does I-Derm Pharma do?
I-Derm Pharma is developing a first-in-class oral therapy for moderate-to-severe psoriasis. Our proprietary small-molecule family targets an inflammatory pathway and has shown strong preclinical efficacy in chimeric mice with psoriatic human skin grafts, alongside a favorable safety profile. We are advancing our lead candidate toward IND with robust IP and are preparing for next milestones and strategic collaborations.
Who founded I-Derm Pharma?
I-Derm Pharma was founded in 2022 by Ofer Sarig (Co-founder & Scientific Advisor), Eli Sprecher (Co-founder & Scientific and Clinical Advisor).
What sector is I-Derm Pharma in?
I-Derm Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences.
Where is I-Derm Pharma located?
I-Derm Pharma is based in Wadi el-Haj St 13, Nazareth, Israel.